Last reviewed · How we verify

NCT06136923

An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer

Completed NA Last updated 13 May 2024
What this trial tests

NA trial testing CT-100-D-004-A in Multiple Sclerosis in 194 participants. Completed in 6 May 2024.

Timeline
19 October 2023
Primary endpoint
18 April 2024
6 May 2024

Quick facts

Lead sponsorClick Therapeutics, Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposebasic science
Enrollment194
Start date19 October 2023
Primary completion18 April 2024
Estimated completion6 May 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Click Therapeutics, Inc.

Who can join

Adults 22 to 65, any sex, with Multiple Sclerosis or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a treatment in future software-based prescription digital therapeutics. One class of CT-100 components are Digital Neuro-activation and Modulation (DiNaMo) components. DiNaMo components target key neural systems (including but not limited to systems related to sensory-, perceptual-, affective-, pain-, attention-, cognitive control, social- and self-processing) to optimally improve a participant's health.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other Click Therapeutics, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06136923.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing